stoxline Quote Chart Rank Option Currency Glossary
  
Grifols, S.A. (GRFS)
7.2  0.09 (1.27%)    05-24 16:00
Open: 7.04
High: 7.225
Volume: 1,136,565
  
Pre. Close: 7.11
Low: 7.01
Market Cap: 6,012(M)
Technical analysis
2024-05-24 4:53:14 PM
Short term     
Mid term     
Targets 6-month :  9.06 1-year :  10.58
Resists First :  7.76 Second :  9.06
Pivot price 7.28
Supports First :  6.74 Second :  6.11
MAs MA(5) :  7.36 MA(20) :  7.09
MA(100) :  7.4 MA(250) :  8.63
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  51.5 D(3) :  66.8
RSI RSI(14): 52.6
52-week High :  12.14 Low :  5.3
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GRFS ] has closed above bottom band by 43.5%. Bollinger Bands are 46.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.24 - 7.29 7.29 - 7.33
Low: 6.89 - 6.95 6.95 - 7.01
Close: 7.1 - 7.2 7.2 - 7.29
Company Description

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Headline News

Mon, 20 May 2024
Grifols, S.A. (NASDAQ:GRFS) Q1 2024 Earnings Call Transcript - Insider Monkey

Sun, 19 May 2024
Is Grifols (GRFS) a Great Value Stock Right Now? - Yahoo Movies UK

Tue, 07 May 2024
Grifols: Why To Watch From The Sidelines (NASDAQ:GRFS) - Seeking Alpha

Sun, 21 Apr 2024
Grifols SA's Related Party Transactions: Navigating Conflicts of Interest and Investor Concerns - TipRanks.com - TipRanks

Fri, 19 Apr 2024
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire

Mon, 25 Mar 2024
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical ... - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 679 (M)
Shares Float 547 (M)
Held by Insiders 0 (%)
Held by Institutions 49.8 (%)
Shares Short 6,710 (K)
Shares Short P.Month 5,970 (K)
Stock Financials
EPS 0.1
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.57
Profit Margin 0.8 %
Operating Margin 12.7 %
Return on Assets (ttm) 2.1 %
Return on Equity (ttm) 2.2 %
Qtrly Rev. Growth 3.2 %
Gross Profit (p.s.) 0
Sales Per Share 9.7
EBITDA (p.s.) 1.51
Qtrly Earnings Growth 178.6 %
Operating Cash Flow 208 (M)
Levered Free Cash Flow -1,260 (M)
Stock Valuations
PE Ratio 72
PEG Ratio 0.2
Price to Book value 0.83
Price to Sales 0.74
Price to Cash Flow 23.47
Stock Dividends
Dividend 0.46
Forward Dividend 0
Dividend Yield 6.3%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android